However, data on their efficacy in patients with BRAF-mutated aNSCLC are limited to small RW studies, which reported response rates of 24% to 35%.13, 14, 15 Thus, the efficacy and safety of ICIs in patients with BRAF-mutated NSCLC remain uncertain. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.